The DSMB's recommendation to continue the Phase 3 study without modifications suggests that Efzofitimod is showing a favorable safety profile and potentially effective outcomes in its trial. This is crucial for aTyr Pharma as positive trial results can lead to regulatory approval and commercialization, significantly impacting the company's valuation and stock price. The news directly impacts investor sentiment and could lead to increased stock price in the short term due to heightened expectations for successful trial outcomes.